US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Ferring Pharmaceuticals

< Previous 1 2 Next >
News headline image
New Real-World Case Series Examines Re-Induction with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Clinical Practice
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Pharmaceuticals and Gallup Announce Landmark Global Public Attitudes Study on Fertility and Family-Building
From Ferring Pharmaceuticals
Via Business Wire
News headline image
U.S. FDA Approves Label Update to Accelerate Thaw Time for ADSTILADRIN® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Announces Update to NCCN Guidelines Expanding Category 2A Recommendation for Nadofaragene Firadenovec-vncg (ADSTILADRIN®) in Patients with BCG-Unresponsive NMIBC
From Ferring Pharmaceuticals
Via Business Wire
News headline image
For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Pharmaceuticals and Theralase® Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
From Ferring Pharmaceuticals
Via Business Wire
News headline image
SUO and Ferring Pharmaceuticals Announce the SUO Non-Muscle Invasive Bladder Cancer (NMIBC) Fellows Research Grant
From Ferring Pharmaceuticals
Via Business Wire
News headline image
With Two in Five Employees Undergoing Fertility Treatment Leaving Their Jobs or Considering Quitting, Are Companies Doing Enough?
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Pharmaceuticals to Explore Strategic Options for Rebyota®
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Highlights New Real-World Research with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Clinical Practice
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Pharmaceuticals Presents Two New Analyses of Pivotal Trial Data for Follitropin Delta (FE 999049) at ASRM 2025
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Presents New Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at ACG 2025
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Presents New Real-World REBYOTA® (fecal microbiota, live – jslm) Data Underscoring Effectiveness and Significant Improvements in Patient Quality of Life
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Expands Growing Body of Real-World Evidence Reinforcing Use of ADSTILADRIN® (nadofaragene firadenovec-vncg) in Urology Practices
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Pharmaceuticals Recognizes World IVF Day by Partnering with Notable Advocates to Amplify the Conversation about Infertility
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Presents New Phase 3b Safety and Effectiveness Data for Recurrent C. Diff Patients Receiving REBYOTA® (fecal microbiota, live – jslm) Via Colonoscopy, and Additional Analyses at DDW
From Ferring Pharmaceuticals
Via Business Wire
News headline image
U.S. FDA Approves Second Drug Product Manufacturing Facility for ADSTILADRIN® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Unveils New Data with ADSTILADRIN® (nadofaragene firadenovec-vncg) at 112th Annual Meeting of the Japanese Urological Association
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin
From Ferring Pharmaceuticals
Via Business Wire
News headline image
First Real-World Outcomes Data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be Presented at 2025 ASCO Genitourinary Cancers Symposium
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Highlights Commitment to C. Diff Infection Community on the Second Anniversary of the Launch of REBYOTA® (fecal microbiota, live – jslm)
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Advances Three Studies in ADSTILADRIN® (nadofaragene firadenovec-vncg) Clinical Trial Program
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Announces U.S. FDA Advisory Committee Meeting for SI-6603 (condoliase), An Investigational Treatment in Lumbar Disc Herniation
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Presents New Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at ACG 2024
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Pharmaceuticals Illustrates Strong Commitment to Advancing Fertility Care at 2024 American Society for Reproductive Medicine Annual Congress
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Presents Real-World Outcomes Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at IDWeek 2024
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study
From Ferring Pharmaceuticals
Via Business Wire
News headline image
Ferring Presents Efficacy and Safety Data From Two Phase 3 Studies for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at NASS 2024
From Ferring Pharmaceuticals
Via Business Wire
< Previous 1 2 Next >